Form 4: Celldex Therapeutics Executive Acquires 78,000 Stock Options

Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, acquired 78,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Summary

• Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, acquired 78,000 incentive stock options on June 13, 2024.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• 25% of the options vest on June 13, 2025, and the remainder vest quarterly over the subsequent 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing related to executive compensation.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
• Employees may view the option grant as a positive sign of the company's commitment to its leadership.

Key Dates